Martin Edwards - Net Worth and Insider Trading

Martin Edwards Net Worth

The estimated net worth of Martin Edwards is at least $6 Million dollars as of 2024-11-13. Martin Edwards is the Director of Verona Pharma PLC and owns about 144,800 shares of Verona Pharma PLC (VRNA) stock worth over $6 Million. Martin Edwards is also the Director of Morphic Holding Inc and owns about 2,376 shares of Morphic Holding Inc (MORF) stock worth over $135,408. Details can be seen in Martin Edwards's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Martin Edwards has not made any transactions after 2023-11-20 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Martin Edwards

To

Martin Edwards Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Martin Edwards owns 6 companies in total, including KalVista Pharmaceuticals Inc (KALV) , Reata Pharmaceuticals Inc (RETA) , and Inozyme Pharma Inc (INZY) among others .

Click here to see the complete history of Martin Edwards’s form 4 insider trades.

Insider Ownership Summary of Martin Edwards

Ticker Comapny Transaction Date Type of Owner
KALV KalVista Pharmaceuticals Inc 2020-10-01 director
RETA Reata Pharmaceuticals Inc 2023-09-26 director
INZY Inozyme Pharma Inc 2020-07-23 director
LIMIT LIMIT 2015-05-05 director
LIMIT LIMIT 2023-11-20 director
LIMIT LIMIT 2023-11-13 director

Martin Edwards Latest Holdings Summary

Martin Edwards currently owns a total of 2 stocks. Among these stocks, Martin Edwards owns 144,800 shares of Verona Pharma PLC (VRNA) as of November 20, 2023, with a value of $6 Million and a weighting of 97.66%. Martin Edwards also owns 2,376 shares of Morphic Holding Inc (MORF) as of November 13, 2023, with a value of $135,408 and a weighting of 2.34%.

Latest Holdings of Martin Edwards

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
VRNA Verona Pharma PLC 2023-11-20 144,800 39.00 5,647,200
MORF Morphic Holding Inc 2023-11-13 2,376 56.99 135,408

Holding Weightings of Martin Edwards


Martin Edwards Form 4 Trading Tracker

According to the SEC Form 4 filings, Martin Edwards has made a total of 3 transactions in Verona Pharma PLC (VRNA) over the past 5 years, including 1 buys and 2 sells. The most-recent trade in Verona Pharma PLC is the acquisition of 33,736 shares on November 20, 2023, which cost Martin Edwards around $62,074.

According to the SEC Form 4 filings, Martin Edwards has made a total of 1 transactions in Morphic Holding Inc (MORF) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Morphic Holding Inc is the acquisition of 2,376 shares on November 13, 2023, which cost Martin Edwards around $48,803.

Insider Trading History of Martin Edwards

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Martin Edwards Trading Performance

GuruFocus tracks the stock performance after each of Martin Edwards's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Martin Edwards is 46.7%. GuruFocus also compares Martin Edwards's trading performance to market benchmark return within the same time period. The performance of stocks bought by Martin Edwards within 3 months outperforms 2 times out of 2 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Martin Edwards's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Martin Edwards

Average Return

No transaction record over 1 Year.

Outperforming Transactions

No transaction record over 1 Year.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 26.53 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) 21.52 LIMIT LIMIT LIMIT LIMIT LIMIT

Martin Edwards Ownership Network

Ownership Network List of Martin Edwards

No Data

Ownership Network Relation of Martin Edwards

Insider Network Chart

Martin Edwards Owned Company Details

What does KalVista Pharmaceuticals Inc do?

Who are the key executives at KalVista Pharmaceuticals Inc?

Martin Edwards is the director of KalVista Pharmaceuticals Inc. Other key executives at KalVista Pharmaceuticals Inc include CFO and Secretary Benjamin L Palleiko , Chief Medical Officer Paul K. Audhya , and Chief Development Officer Christopher Yea .

KalVista Pharmaceuticals Inc (KALV) Insider Trades Summary

Over the past 18 months, Martin Edwards made no insider transaction in KalVista Pharmaceuticals Inc (KALV). Other recent insider transactions involving KalVista Pharmaceuticals Inc (KALV) include a net purchase of 1,251,017 shares made by Venrock Healthcare Capital Partners Iii, L.p. , a net sale of 144,760 shares made by Benjamin L Palleiko , and a net sale of 116,267 shares made by Edward P. Feener .

In summary, during the past 3 months, insiders sold 40,693 shares of KalVista Pharmaceuticals Inc (KALV) in total and bought 0 shares, with a net sale of 40,693 shares. During the past 18 months, 583,370 shares of KalVista Pharmaceuticals Inc (KALV) were sold and 1,251,017 shares were bought by its insiders, resulting in a net purchase of 667,647 shares.

KalVista Pharmaceuticals Inc (KALV)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

KalVista Pharmaceuticals Inc Insider Transactions

No Available Data

Martin Edwards Mailing Address

Above is the net worth, insider trading, and ownership report for Martin Edwards. You might contact Martin Edwards via mailing address: 15 New England Executive Park, Burlington Ma 01803.